Reduced p53 tumor suppressor function and constitutive activation of BCL6 oncoprotein may represent alternative oncogenic mechanisms by which CBP/p300 mutations contribute to DLBCL transformation. This evidence concerns the gene TP53 and diffuse large B-cell lymphoma.